We selected the BIONi010‐C‐2 (APOE3/3) cell line to detect early changes in Alzheimer's disease (AD) pathology markers, such as amyloid beta or tau aggregation, upon exposure of the matured organoids to increased norepinephrine (NE). This evidence concerns the gene MAPT and Alzheimer disease.